EMD Serono launches male fertility education campaign

Share this article:
EMD Serono launches male fertility education campaign
EMD Serono launches male fertility education campaign
EMD Serono is partnering with Men's Health Network on a patient education campaign aimed at raising awareness of male infertility.

The effort, dubbed “In The Know: What No One Tells You About Male Fertility,” is launching this week, which is Men's Health Week. The campaign features a 20-page booklet written in conjunction with the Society for the Study of Male Reproduction, a website (www.FertilityLifeLines.com/intheknow) and a PR campaign by Baer Consulting. It's being supported by a satellite media tour, and aimed at reaching couples through health titles and local news outlets.

FertilityLifeLines.com is EMD Serono's fertility awareness site, and includes branding for Gonal-f, a hormone treatment indicated for both male and female infertility. Patients can get the booklet by registering at the site or by calling a toll-free number. EMD Serono reps are distributing copies to reproductive endocrinologists, and the company is promoting it online through search engine optimization and banner ads. 

As part of the effort, EMD Serono and Men's Health Network are touting a survey finding that 45% of men say they would wait a year or more to seek treatment for an infertility problem. Men are much less likely to present than women, said EVP, endocrinology David Stern, and for women in their late 30s and older, time is critical.

"Some of this is embarassment," said Stern. "It's important to talk about it. It's not something that makes you less manly. It's common and can be treated."

About one in eight couples – around 7.3 million Americans -- has trouble conceiving, the company said, and half of those cases have to do with male fertility issues – often easily treatable ones.  

The campaign grew out of an earlier “girlfriend-to-girlfriend” effort, aimed at women and based on research conducted with Conceive Magazine, that launched last year.
Share this article:

Email Newsletters

More in News

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.